Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
Alberto Cruz‐Bermúdez(Hospital Universitario Puerta de Hierro Majadahonda), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 215
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
|Circulation|2019|344
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
|Free Radical Biology and Medicine|2018|140
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
|Translational Lung Cancer Research|2022|19